Sagimet Biosciences Inc. Series A Common Stock
SGMTSagimet Biosciences Inc. Series A (SGMT) is a biotechnology company focused on developing innovative therapies for metabolic and fibrotic diseases. The company specializes in targeting liver and metabolic disorders through novel small molecule drugs, aiming to address unmet medical needs in these areas.
Company News
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced its inclusion in the Russell 3000 and Russell 2000 indexes effective June 29, 2026. The clinical-stage biopharmaceutical company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026. The company has sufficient capital to fund operations t...
Sagimet Biosciences announced management participation in the Leerink Partners Therapeutics Forum on July 15, 2026. The company also approved an inducement grant of 34,300 stock options to two newly hired employees as part of their employment compensation packages.
Sagimet Biosciences appointed Dr. Andreas Grauer as Chief Medical Officer effective April 20, 2026, replacing retiring Dr. Eduardo Martins who will serve as external scientific advisor. Grauer brings over two decades of biopharmaceutical leadership experience from roles at Omeros, Federation Bio, Corcept Therapeutics, and Amgen. He received an in...
Sagimet Biosciences announced presentations of Phase 2b FASCINATE-2 trial data on denifanstat for MASH at the Fueling MASH Keystone Symposium in Vancouver. The data shows that denifanstat-treated MASH patients who were histological responders demonstrated significant reduction in glycine- and taurine-conjugated bile acids, suggesting potential us...
Sagimet Biosciences announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. The company is developing FASN inhibitors, with denifanstat meeting primary endpoints in Phas...
